Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 3 5Phase 1 2Phase NA 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 10CNS 8Sarcoma 5Dermatologic 2Plasma cell 1Other hematologic neoplasm 1Breast 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1Infections 1

Interventions

Dexamethasone 141Lenalidomide 60Bortezomib 56Calcium Dobesilate 47Melphalan 44carfilzomib 40pomalidomide 39Cyclophosphamide 38daratumumab 27belantamab mafodotin 22ixazomib 19Peripheral Blood Stem Cell Transplantation 18fludarabine phosphate 16fludarabine 16dexamethasone acetate 14Bendamustine Hydrochloride 14Whole-Body Irradiation 13Filgrastim 13dexamethasone 21-phosphate 12Tacrolimus 12venetoclax 11auricularum 11Prednisone 11selinexor 10liposomal doxorubicin 10iberdomide 10Mycophenolic Acid 10Cyclosporine 9pembrolizumab 8isatuximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carmustine × Plasma cell × Clear all
NCT00046852 2019-11-04

Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma

University of Maryland, Baltimore

Phase 1/2 Completed
Plasma cell

Infections, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡